Research Topics
Genomes and Genes
Species | Gerald G KruegerSummaryAffiliation: University of Utah Country: USA Publications
| Collaborators
|
Detail Information
Publications
Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasisGerald G Krueger
Department of Dermatology, University of Utah Health Sciences Center, 50 N Medical Drive, Suite 4B 454, Salt Lake City, UT 84132, USA
Expert Opin Biol Ther 2:431-41. 2002..Alefacept did not alter the primary or acquired immune response in psoriatic patients. Clinical data obtained to date support the use of alefacept as a safe and remittive therapy for psoriasis...- A human interleukin-12/23 monoclonal antibody for the treatment of psoriasisGerald G Krueger
University of Utah, Salt Lake City, USA
N Engl J Med 356:580-92. 2007..Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis... - Current concepts and review of alefacept in the treatment of psoriasisGerald G Krueger
Department of Dermatology, 4B454 School Medicine, University of Utah Health Sciences Center, 30 N 1900 E, Salt Lake City, UT 84132 2409, USA
Dermatol Clin 22:407-26, viii. 2004.... 
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasisHowa Yeung
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
J Am Acad Dermatol 68:64-72. 2013..Despite widespread dissatisfaction and low treatment persistence in moderate to severe psoriasis, patients' reasons behind treatment discontinuation remain poorly understood...
Association between IL13 polymorphisms and psoriatic arthritis is modified by smokingKristina Callis Duffin
Department of Dermatology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, Utah 84132, USA
J Invest Dermatol 129:2777-83. 2009..88, P=0.74, CC/non-smoker, prevalence 42% (reference), CC/smoker prevalence 47%, OR 1.21, P=0.47). This study suggests that IL13 polymorphisms associate most strongly with PsA and that smoking may modulate this effect...- Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasisKatrina Abuabara
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
J Am Acad Dermatol 68:262-9. 2013..Physician perceptions can influence prescribing patterns and patient outcomes, and may help to explain variations in clinical practice... - Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice settingJoel M Gelfand
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
Arch Dermatol 148:487-94. 2012..To compare the effectiveness of biologic systemic therapy, nonbiologic systemic therapy, and phototherapy for treatment of psoriasis... - Genome-wide association analysis identifies three psoriasis susceptibility lociPhilip E Stuart
Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA
Nat Genet 42:1000-4. 2010..We also replicated a recently identified association signal near RNF114 (rs495337, combined P = 2 × 10⁻⁷)... - A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasisGerald G Krueger
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT 84132 2409, USA
J Dermatolog Treat 19:146-55. 2008..To evaluate the safety and efficacy of multiple courses of alefacept in combination with traditional psoriasis therapy for the treatment of chronic plaque psoriasis (CPP)... - Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patientsJoy Wan
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA
J Am Acad Dermatol 66:376-86. 2012..Despite increasing therapies for moderate to severe psoriasis, dermatologists' treatment preferences are unknown... - Alefacept: a novel biologic in the treatment of psoriasisClive M Liu
Department of Dermatology, University of Utah, 30 North 1900 East #4B454, Salt Lake City, UT 84132, USA
Drugs Today (Barc) 40:961-74. 2004..This selective effect on the immune system distinguishes alefacept from immunosuppressive therapies that are nonselective... - Obesity in early adulthood as a risk factor for psoriatic arthritisRazieh Soltani-Arabshahi
Department of Dermatology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, UT 84132, USA
Arch Dermatol 146:721-6. 2010..To study whether obesity increases the risk of psoriatic arthritis (PsA), given that obesity is a risk factor for psoriasis and is associated with more severe disease... - Consensus guidelines for the management of plaque psoriasisSylvia Hsu
Department of Dermatology, Baylor College of Medicine, Houston, TX 77030, USA
Arch Dermatol 148:95-102. 2012.... - Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypesTanya E Christensen
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah 84132-2409, USA
J Invest Dermatol 126:2397-403. 2006.... - Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide associationKristina Callis Duffin
4A330 School of Medicine, Salt Lake City, UT 84132, USA
Dermatol Ther 23:101-13. 2010..Many of these genetic variations also associate with immune disorders considered psoriatic co-morbidities, including Crohn's disease and diabetes... - A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisGerald G Krueger
University of Utah Health Sciences Center, Salt Lake City, USA
J Am Acad Dermatol 47:821-33. 2002..In previous phase II studies, alefacept significantly improved psoriasis and was well tolerated. The clinical response to alefacept was durable... - Development and use of alefacept to treat psoriasisGerald G Krueger
Department of Dermatology, University of Utah Health Sciences Center, 4B454 School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132-2409, USA
J Am Acad Dermatol 49:S87-97. 2003..Adverse events in the placebo and active treatment arms did not differ. We conclude that alefacept significantly improves psoriasis and produces durable clinical improvement with a very favorable safety profile... - A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisChristopher S Carlin
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA
J Am Acad Dermatol 50:859-66. 2004..We conclude that PASI 50 equates to a clinically meaningful improvement in psoriasis and represents a discerning primary endpoint... - Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathwaysRajan P Nair
Department of Dermatology, University of Michigan, Ann Arbor, Michigan 48109, USA
Nat Genet 41:199-204. 2009..Our results expand the catalog of genetic loci implicated in psoriasis susceptibility and suggest priority targets for study in other auto-immune disorders... - National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball
Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA
J Am Acad Dermatol 58:1031-42. 2008.... - The effect of hair color on the incorporation of codeine into human hairDouglas E Rollins
Department of Pharmacology and Toxicology University of Utah Health Sciences Center, Salt Lake City, Utah 84112, USA
J Anal Toxicol 27:545-51. 2003..The incorporation of these drugs into hair should be studied carefully in humans to ensure the appropriate interpretation of drug concentrations... - Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasisKristina Callis Duffin
Department of Dermatology, University of Utah, Salt Lake City, Utah 84132, USA
J Am Acad Dermatol 60:604-8. 2009..We sought to determine what clinical features of psoriasis predict sleep interference... - Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trialGerald G Krueger
University of Utah Health Sciences Center, Salt Lake City, Utah 84132 0001, USA
J Am Acad Dermatol 54:S112-9. 2006..Etanercept provides rapid, significant improvement in psoriatic symptoms and disease... - Impact of obesity and smoking on psoriasis presentation and managementMark D Herron
Department of Dermatology, University of Utah School of Medicine, Health Sciences Center, 30 North 1900 East, Salt Lake City, UT 84132, USA
Arch Dermatol 141:1527-34. 2005.... - A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamageSewon Kang
University of Michigan Medical Center, Department of Dermatology, Ann Arbor, Michigan 48109 0314, USA
J Am Acad Dermatol 52:268-74. 2005..Previous studies indicate that tazarotene is efficacious in reducing signs of photodamage. Objective We sought to confirm the efficacy and tolerability of tazarotene 0.1% cream in the treatment of facial photodamage... - The remittive effects of alefaceptGerald G Krueger
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
J Cutan Med Surg 8:10-3. 2004..Alefacept is a remittive therapy for psoriasis... - Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritisDaniel Zaghi
Department of Dermatology, School of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
J Drugs Dermatol 11:160-7. 2012..This is a concise and current review of ustekinumab in the treatment of plaque psoriasis and psoriatic arthritis, with focus on data from the seven published clinical trials... - Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide associationKristina Callis Duffin
Department of Dermatology, School of Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah 84132 2409, USA
J Invest Dermatol 129:827-33. 2009..These discoveries pose the challenge of elucidating the role of common genetic variants in susceptibility to and manifestations of psoriasis... - Summary of minutes of the GRAPPA meeting adjacent to the American Academy of Dermatology 67th Annual MeetingWolf Henning Boehncke
Department of Dermatology, Boston Medical Center, Boston University School of Medicine, Boston, MA 02118, USA
J Rheumatol 38:553-6. 2011..Key results and minutes of the San Francisco meeting were presented at the 2009 GRAPPA annual meeting in Stockholm, Sweden, and are summarized here... - Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitisGerald G Krueger
University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
J Drugs Dermatol 6:185-93. 2007..To characterize the pharmacokinetics of tacrolimus after topical application in adult and pediatric patients with moderate to severe atopic dermatitis from all clinical trials in which tacrolimus blood levels were obtained... - From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl
Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
J Am Acad Dermatol 58:94-105. 2008..Biologics are widely used in the treatment of psoriasis and psoriatic arthritis... - A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approachBruce Strober
Department of Dermatology, New York University Medical Center, New York, NY, USA
J Am Acad Dermatol 61:S1-S46. 2009..The final rankings and analysis provide guidance for practical, safe, and efficacious treatment options in a number of complex psoriasis scenarios... - Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasisJessica A Walsh
Division of Rheumatology and the Department of Dermatology, University of Utah, Salt Lake City, UT 84109, USA
J Rheumatol 40:287-93. 2013..To compare the abilities of 3 validated screening instruments to predict the diagnosis of psoriatic arthritis (PsA) in patients with psoriasis... - Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimodMark D Herron
University of Utah, Department of Dermatology, School of Medicine, Salt Lake City, UT, USA
Int J Dermatol 43:300-2. 2004..Patients with seborrheic keratoses frequently desire an effective topical therapy for seborrheic keratoses... - Efficacy of acitretin and commercial tanning bed therapy for psoriasisChristopher S Carlin
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, 84132, USA
Arch Dermatol 139:436-42. 2003..To assess the efficacy of acitretin and commercial tanning bed therapy for the treatment of moderate to severe chronic plaque-type psoriasis... - Genetics of psoriasis and psoriatic arthritis: update and future directionKristina Callis Duffin
Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
J Rheumatol 35:1449-53. 2008..This article is a summary of that presentation and a review of the literature... - Multiple Loci within the major histocompatibility complex confer risk of psoriasisBing Jian Feng
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA
PLoS Genet 5:e1000606. 2009..These results demonstrate that there are at least two additional loci within the MHC conferring risk of psoriasis... - Induction of dramatic hyperpigmentation in a patient with generalized lichen planus treated with re-PUVAChristopher S Carlin
Department of Dermatology, University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA
J Cutan Med Surg 6:125-7. 2002.... - An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyBernard Goffe
Dermatolog Associates, Seattle, Washington 98101, USA
Clin Ther 27:1912-21. 2005..Information on longer-term safety and tolerability is needed to confidently prescribe alefacept therapy for chronic plaque psoriasis beyond 1 or 2 courses... - Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritisArthur Kavanaugh
Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA
J Rheumatol 33:2254-9. 2006..To examine the effect of infliximab on employment status, time lost from work, and productivity in a double-blind, placebo-controlled study of patients with active psoriatic arthritis (PsA)... - A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasisMark Lebwohl
Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
Int J Dermatol 41:269-74. 2002..A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis... - A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb
Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, 08901 0019, USA
Arch Dermatol 139:1627-32; discussion 1632. 2003..To determine safety and efficacy of monotherapy with etanercept... - Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein
University of California, Irvine, USA
J Am Acad Dermatol 48:760-7. 2003..Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream... - Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatmentGerald G Krueger
Health News 10:10-1. 2004 - Keratoderma blennorrhagicumScott R Florell
N Engl J Med 349:2367-8. 2003 - Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Kim A Papp
Probity Medical Research, Waterloo and University of Western Ontario, London, ON, Canada
Lancet 371:1675-84. 2008..This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders... - Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trialSteven R Feldman
Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1071, USA
J Am Acad Dermatol 53:887-9. 2005..At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life... - Consensus on a core set of domains for psoriatic arthritisDafna D Gladman
J Rheumatol 34:1167-70. 2007..quot;.. - AAD consensus statement on psoriasis therapiesJeffrey P Callen
J Am Acad Dermatol 49:897-9. 2003 - A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genesMichele Cargill
Celera, Alameda, CA 94502, USA
Am J Hum Genet 80:273-90. 2007..These data, and the previous observation that administration of an antibody specific for the IL-12p40 subunit to patients with psoriasis is highly efficacious, suggest that these genes play a fundamental role in psoriasis pathogenesis... - The 5q31 variants associated with psoriasis and Crohn's disease are distinctYonghong Li
Celera, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
Hum Mol Genet 17:2978-85. 2008..These results identify the most significant 5q31 risk variants for psoriasis and suggest that distinct 5q31 variants contribute to CD and psoriasis risk... - An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvestingNicholas R Benson
DermTech International, La Jolla, California 92037, USA
J Invest Dermatol 126:2234-41. 2006..Data demonstrate that tape stripping reveals mRNA markers not detected in biopsy samples and thus the method may be a useful supplement to biopsy...